9. SEGMENT REPORTING (Details - Percentage breakdown) - Sales Revenue, Net [Member]	3 Months Ended	6 Months Ended
Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2016	Oct. 31, 2015
Customer revenue as a percentage of revenue	100.00%	100.00%	100.00%	100.00%
Halozyme Therapeutics [Member]
Customer revenue as a percentage of revenue	77.00%	56.00%	74.00%	70.00%
Customer A [Member]
Customer revenue as a percentage of revenue	10.00%	41.00%	14.00%	28.00%
Customer B [Member]
Customer revenue as a percentage of revenue	12.00%		10.00%
Other Customers [Member]
Customer revenue as a percentage of revenue	1.00%	3.00%	2.00%	2.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration